Agenus Inc - ESG Rating & Company Profile powered by AI
The page contains a free Environmental, Social and Governance analysis for Agenus Inc. If you work at Agenus Inc and you would like to licence your Sustainability rating, please contact us. This dashboard contains a Q&A table on Agenus Inc.
Agenus Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.5; made up of an environmental score of 4.0, social score of 4.8 and governance score of 1.6.
3.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1144 | Veerhealth Care Ltd | 3.6 | Medium |
| 1144 | iStreet Network Ltd | 3.6 | Medium |
| 1186 | Agenus Inc | 3.5 | Medium |
| 1186 | CRISPR Therapeutics AG | 3.5 | Medium |
| 1186 | Catalent Inc | 3.5 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Agenus Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Agenus Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Agenus Inc report the average age of the workforce?
Sign up for free to unlockDoes Agenus Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Agenus Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Agenus Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Agenus Inc offer flexible work?
Sign up for free to unlockDoes Agenus Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Agenus Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Agenus Inc conduct supply chain audits?
Sign up for free to unlockDoes Agenus Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Agenus Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Agenus Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Agenus Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Agenus Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Agenus Inc disclose water use targets?
Sign up for free to unlockDoes Agenus Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Agenus Inc have a product recall in the last two years?
Sign up for free to unlockDoes Agenus Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Agenus Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Agenus Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Agenus Inc disclose parental leave metrics?
Sign up for free to unlockDoes Agenus Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Agenus Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Agenus Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Agenus Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Agenus Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Agenus Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Agenus Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Agenus Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Agenus Inc disclose its waste policy?
Sign up for free to unlockDoes Agenus Inc report according to TCFD requirements?
Sign up for free to unlockDoes Agenus Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Agenus Inc disclose energy use targets?
Sign up for free to unlockDoes Agenus Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Agenus Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Agenus Inc
These potential risks are based on the size, segment and geographies of the company.
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.